U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N
Molecular Weight 135.2062
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVAMFETAMINE

SMILES

C[C@@H](N)CC1=CC=CC=C1

InChI

InChIKey=KWTSXDURSIMDCE-MRVPVSSYSA-N
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m1/s1

HIDE SMILES / InChI

Description

LEVAMFETAMINE the levorotatory form of amphetamine. L-amphetamine, is a central nervous system (CNS) stimulant known to increase wakefulness and concentration in association with decreased appetite and fatigue. Pharmaceuticals that contain levoamphetamine are currently indicated and prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy in some countries. L-Amphetamine succinate was sold in Hungary between 1952 and 1955 under the brand name Cydril.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.3 µM [EC50]
Conditions
PubMed

PubMed

TitleDatePubMed
New approaches in the management of multiple sclerosis.
2010 Nov 24
Patents

Patents

Sample Use Guides

In Vivo Use Guide
In children from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained. In children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.
Route of Administration: Oral
In Vitro Use Guide
TAAR1 receptor activation was assayed in CHO cells stably expressing Gα16 and the hTAAR1 receptor. Cells were plated in HAM’s F-12 medium with 10% fetal bovine serum, 400 µg/ml hygromycin, and 400 µg/ml geneticin at 30,000 cells/well in 96-well, black, clear-bottom plates and incubated at 37 °C 5% CO2 overnight. Activation of hTAAR1 via LEVAMFETAMINE was assessed the next day using the Calcium 3 Assay Kit (Molecular Devices). On the day of assay, the culture medium was removed and the cells washed once in 100 µl HBSS buffer containing 0.78 mg/ml probenicid, followed by the addition of 100 µl HBSS buffer plus probenicid and 100 µl of Calcium 3 dye (one-third the suggested concentration). The cells were incubated with the dye at 37 °C for 1 h. LEVAMFETAMINE were evaluated using 10 different concentrations run in duplicate.
Name Type Language
LEVAMFETAMINE
INN  
INN  
Official Name English
LEVAMFETAMINE [INN]
Common Name English
AMPHETAMINE L-FORM [MI]
Common Name English
(-)-(R)-.ALPHA.-METHYLBENZENEETHANAMINE
Systematic Name English
AMFETAMINE, (R)-
Common Name English
LEVAMPHETAMINE
Common Name English
(-)-(R)-.ALPHA.-METHYLPHENETHYLAMINE
Systematic Name English
AMPHETAMINE L-FORM
MI  
Common Name English
Classification Tree Code System Code
CFR 21 CFR 310.502
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
Code System Code Type Description
EVMPD
SUB08453MIG
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY
ChEMBL
CHEMBL19393
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY
INN
1313
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY
MERCK INDEX
M1849
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY Merck Index
PUBCHEM
32893
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY
CAS
156-34-3
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY
ECHA (EC/EINECS)
205-850-8
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY
EPA CompTox
156-34-3
Created by admin on Tue Oct 22 14:22:20 UTC 2019 , Edited by admin on Tue Oct 22 14:22:20 UTC 2019
PRIMARY